Supernus Pharmaceuticals Earnings: Expect Strong Beats

Supernus Pharmaceuticals earnings report this Tuesday could be a game-changer, with analysts predicting a 28.8% year-over-year revenue growth, following a 20.5% increase last quarter. Despite peers like Eli Lilly and Merck outperforming, Supernus stock has lagged, down 5.3% in the past month. A strong earnings report could spark a turnaround, with a price target of $62.67. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/30445adcd61090ba